Compare NOTE & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTE | BCTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 28.8M |
| IPO Year | N/A | N/A |
| Metric | NOTE | BCTX |
|---|---|---|
| Price | $1.22 | $4.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $29.25 | ★ $40.00 |
| AVG Volume (30 Days) | 261.7K | ★ 1.1M |
| Earning Date | 03-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,673,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.60 | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $4.04 |
| 52 Week High | $24.36 | $98.20 |
| Indicator | NOTE | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 37.18 |
| Support Level | $1.17 | $4.04 |
| Resistance Level | $1.29 | $4.42 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 33.08 | 0.89 |
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.